Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib with paclitaxel, carboplatin and radiotherapy in first-line treatment of locally advanced cervical cancer
ChiCTR2500108685Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital Airport Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trilaciclib in Cervical Cancer (CC), sponsored by Tianjin Medical University Cancer Institute and Hospital Airport Hospital. Primary endpoint: Incidence of grade ≥3 neutropenia during first-line chemotherapy treatment. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500108685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108685.